569684-10-2

Upstream product

• 98-80-6 phenylboronic acid 
• 569683-98-3 6-[3,5-bis(trifluoromethyl)benzyl]-4-chloro-2-methylthio-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-one 
• 313339-35-4 4,6-dichloro-2-(methylsulfanyl)pyrimidine-5-carboxylic acid 
• 6299-25-8 4,6-Dichloro-2-(methylthio)pyrimidine 

Downstream Products

• 569684-22-6 6-[3,5-bis(trifluoromethyl)benzyl]-2-methylsulfonyl-4-phenyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-one 

Relevant academic research and scientific papers

Design, synthesis, and evaluation of novel 2-substituted-4-aryl-6,7,8,9- tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-ones as NK1 antagonists

A series of novel bicyclic pyrimidine derivatives was prepared as part of a search for NK1 antagonist aimed at the treatment of urinary incontinence. Among them, 3g, a pyrimido[4,5-b][1,5]oxazocine derivative, bearing a 4-acetylpiperazinyl grou

FUSED BICYCLIC PYRIMIDINE DERIVATIVES

A novel fused bicyclic pyrimidine derivative or a salt thereof that acts as a tachykinin receptor antagonist and, in particular, as an NK1 receptor antagonist is represented by the following general formula (1): wherein the rings A and B are each a benzene ring having 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring); the ring C is a nitrogen-containing ring; m is 1 or 2; and n is 2 or 3.